Patients don’t ask “What’s the patent life left?”—they ask, “Can I get my medicine cheaper, sooner, or without interruption?”
That’s the real story behind the surge in online searches about “drug switching.” And it’s why the questions patients are aski…

Evergreen the brand. Beat the brand. The difference is whether you treat patent intelligence as a spreadsheet—or as an early-warning system.
Drug patent “evergreening” is no longer a surprise tactic; it’s a playbook. Brands don’t just defend a molecule…

GPT, Rosalind, and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry is used to hype cycles. But this one matters—not because it promises “AI cures,” but because it could quietly change how generic drugs get m…

Patent cliffs don’t just erase revenue—they rewrite the competitive map.
When a blockbuster’s exclusivity window closes, the market doesn’t “wait” for your next launch. It reacts—fast. Payers tighten formularies, PBMs renegotiate aggressively, and co…

OpenAI’s GPT just did something that should make every pharma IP team sit up: it “smashed” drug patent cliffs—by accelerating the work that used to take years.
That’s the headline from DrugPatentWatch’s latest post on how GPT and Rosalind are being use…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
The market doesn’t just react to patent litigation—it anticipates it. And in the pharmaceutical industry, the most dangerous surprises rarely arrive with a h…

Most people think “patent life” is a single number. In the GCC, it’s not.
If you’re a pharma leader, a brand team, or an investor, you already know the headline: patents expire, generics arrive. But the real question isn’t “How long is the patent?”—it’…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “innovating.” They’re extending. Here are 4 signals to watch.
In pharma, the most expensive word in the room is often the quietest one: extension.
A new formulation, a tweak to dosing, a fresh patent filing—these can look like pro…

Biopharma teams don’t lose deals because they lack ambition. They lose because they mis-time the pitch.
In licensing, partnering, and commercial strategy, timing is everything—especially when the product’s “go-to-market” isn’t just about clinical data …